2. Kelley Angela S, Smith Yolanda R, Padmanabhan Vasantha. A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019;104:5299-315.
3. Reis AM, Honorato-Sampaio K. C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. J Clin Sci. 2018;132:905-8.
5. Underdal MO, Salvesen Ø, Schmedes A, Andersen MS, Vanky E. Prolactin and breast increase during pregnancy in PCOS: linked to long-term metabolic health? J Eur J Endocrinol. 2019;180:373-80.
6. Zhang L, Fang X, Li L, Liu R, Zhang C, Liu H, Tan M, Yang G. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. J Endocrinol Invest. 2018;41:1401-7.
6. Li M, Yang M, Zhou X, Fang X, Hu W, Zhu W, Wang C, Liu D, Li S, Liu H, Yang G, Li L. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:1485-93.
8. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). J Hum Reprod. 2004;19:41-7.
9. Stefan N, Haring H. The role of hepatokines in metabolism. J Nat Rev Endocrinol. 2013;9:144–52.
10. Jialal I, Devaraj S, Bettaieb A, Haj F, Adams-Huet B. Increased adipose tissue secretion of Fetuin-A, lipopolysaccharide-binding protein and high-mobility group box protein 1 in metabolic syndrome. J Atherosclerosis. 2015;241:130–7.
11. Perez-Sotelo D, Roca-Rivada A, Larrosa-Garcia M, Castelao C, Baamonde I, Baltar J, Crujeiras AB, Seoane LM, Casanueva FF, Pardo M. Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity. J Endocrine. 2017;55:435–46.
13. Pal D , Dasgupta S , Kundu R , et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. J Nature Medicine. 2012;18:1279-85.
18. Yoo HJ, Choi KM. Hepatokines as a link between obesity and cardiovascular diseases. J Diabetes Metab J. 2015;39:10–15.
20. von Loeffelholz C, Horn P,Birkenfeld A L et al. Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease. J J Invest Surg. 2016;29:266-74.
22. Díaz Marta, Gallego-Escuredo José Miguel, López-Bermejo Abel et al. Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome. J Int J Endocrinol. 2018:4192940.
25. Wild Robert A, Carmina Enrico, Diamanti-Kandarakis Evanthia et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J J Clin Endocrinol Metab. 2010; 95: 2038-49.
26. Albareda M, Rodríguez-Espinosa J, Murugo M et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. J Diabetologia. 2000; 43: 1507-11.
28.Mi Qiao, Li Yanxin, Wang Miao et al. Circulating C1q/TNF-related protein isoform 15 is a marker for the presence of metabolic syndrome. J Diabetes Metab Res Rev. 2019; 35: e3085.
30. Lai Y, Chen J, Li L, Yin J, He J, Yang M, Jia Y, Liu D, Liu H, Liao Y, Yang G. Circulating Zinc-α2-glycoprotein levels and Insulin Resistance in Polycystic Ovary Syndrome. Sci Rep. 2016; 6: 25934.
36. Jensen MK, Bartz TM, Mukamal KJ, Djoussé L, Kizer JR, Tracy RP, Zieman SJ, Rimm EB, Siscovick DS, Shlipak M, Ix JH. Fetuin-A, type 2 diabetes, and risk of cardiovascular diseasein older adults: the cardiovascular health study. J Diabetes Care. 2013; 36: 1222-8.
37. Jensen Majken K, Bartz Traci M, Djoussé Luc et al. Genetically elevated fetuin-A levels, fasting glucose levels, and risk of type 2 diabetes: the cardiovascular health study. J Diabetes Care. 2013; 36: 3121-7.
38. Kozakowski J, Jeske W, Zgliczyski W. Fetuin-A levels in lean and obese women with polycystic ovary syndrome. J Endokrynologia Polska, 2014; 65: 371-6.